A study of Bone Health on Aromatase Inhibitors
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2023/06/054340
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1) ER/PR unknown status
2) Evidence of distant metastasis
3) Past history of other hormonal therapy
4) Patients with uncontrolled cardiac disease
5) Other significant malignancies within the past 3 years or other serious illnesses like
uncontrolled diabetes or chronic renal disease
6) Patients with diseases that require chronic intake of drugs that interfere with bone
metabolism
1) ER/PR unknown status
2) Evidence of distant metastasis
3) Past history of other hormonal therapy
4) Patients with uncontrolled cardiac disease
5) Other significant malignancies within the past 3 years or other serious illnesses like
uncontrolled diabetes or chronic renal disease
6) Patients with diseases that require chronic intake of drugs that interfere with bone
metabolism
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome of the study is to understand the incidence of osteoporosis in Indian postmenopausal population and effect of Aromatase inhibitors on the incidence of osteoporosisTimepoint: A baseline DEXA scan will be obtained as a part of routine work up before stating AIs <br/ ><br>A repeat baseline BMD scan will be done at 12 months and at 2 years after starting AIs
- Secondary Outcome Measures
Name Time Method ot ApplicableTimepoint: Not Applicable